A phase I trial to evaluate the safety and immunogenicity of the HIV-1 pGA2/JS2 plasmid DNA vaccine [HIV DNA vaccine] given intramuscularly (IM) in HIV-1 uninfected adults

Trial Profile

A phase I trial to evaluate the safety and immunogenicity of the HIV-1 pGA2/JS2 plasmid DNA vaccine [HIV DNA vaccine] given intramuscularly (IM) in HIV-1 uninfected adults

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2013

At a glance

  • Drugs PGA2-JS2 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Aug 2013 Planned End Date changed to 1 Apr 2003.
    • 13 Nov 2008 Last checked against ClinicalTrials.gov record.
    • 18 Jun 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top